Commercial Launch of COVID-19 Antibody Test

NASDAQ:PRPO   Precipio, Inc
Precipio Announces Commercial Launch of COVID-19 Antibody Test

PRPO entered into an agreement with ADS Biotec, a US company based in Omaha, Nebraska, to distribute its FDA-authorized COVID-19 serology antibody tests that recently received EUA (Emergency Use Authorization). Distribution of the product will take place in the US as well as in other markets worldwide.

Precipio will begin rolling out these antibody tests initially as a CLIA test run in its laboratory (expected launch August); then further roll out (pending further FDA authorization) to physician offices as a POC (point-of-care) test; and finally, through distribution via various retail channels for at-home, DTC (direct-to-consumer) use.

A recent Harvard University study indicates the need from 5 to 20 Million tests per day in the US. Current laboratory testing capacity in the US is estimated at only several hundred thousand per day. We believe that the only way to deliver testing at the scale required to achieve proper testing capacity would be through at-home use.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.